Overview

Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab